Thus, our results identified a potentially novel mechanism of the therapeutic action of indirubin in the treatment of ITP through regulating the homeostasis of CD4+ T cells in a PD1/PTEN/AKT signalling pathway. The gene discussed is AKT1; the disease is autoimmune thrombocytopenic purpura.